CytomX Therapeutics Hits New 52-Week High at $4.16

CytomX Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 4.16 on November 3, 2025. This achievement underscores the company's notable performance in the pharmaceuticals and biotechnology sector, particularly as it has seen a remarkable 141.1% increase over the past year, significantly outpacing the S&P 500's performance of 19.89%.
With a market capitalization of USD 360 million, CytomX operates within the microcap segment, showcasing a price-to-earnings (P/E) ratio of 10.00. The company maintains a strong return on equity at 40.02%, indicating effective management of shareholder equity. Additionally, the price-to-book ratio stands at 3.00, reflecting the company's valuation relative to its assets.

CytomX's financial metrics, including a debt-to-equity ratio of -1.27, suggest a solid financial position, while the absence of a dividend yield indicates a focus on reinvestment rather than returning capital to shareholders. This recent high marks a pivotal moment for CytomX as it continues to navigate the competitive landscape of its industry.